BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007;139:55-63. [DOI: 10.1111/j.1365-2141.2007.06747.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Targeted therapies in multiple myeloma. Target Oncol 2009;4:23-36. [PMID: 19343299 DOI: 10.1007/s11523-008-0102-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
2 Wang J, Zhao Y, Kauss MA, Spindel S, Lian H. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. European Journal of Cell Biology 2009;88:103-15. [DOI: 10.1016/j.ejcb.2008.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
3 Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget 2015;6:24205-17. [PMID: 26090869 DOI: 10.18632/oncotarget.4434] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
4 Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple myeloma. Expert Review of Hematology 2014;7:113-25. [DOI: 10.1586/17474086.2013.874943] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
5 Binder NB, Niederreiter B, Hoffmann O, Stange R, Pap T, Stulnig TM, Mack M, Erben RG, Smolen JS, Redlich K. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med 2009;15:417-24. [PMID: 19330010 DOI: 10.1038/nm.1945] [Cited by in Crossref: 130] [Cited by in F6Publishing: 117] [Article Influence: 10.0] [Reference Citation Analysis]
6 Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008;19:263-76. [PMID: 18514565 DOI: 10.1016/j.cytogfr.2008.04.006] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 6.8] [Reference Citation Analysis]
7 Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008;283:32628-36. [PMID: 18812315 DOI: 10.1074/jbc.M806266200] [Cited by in Crossref: 139] [Cited by in F6Publishing: 94] [Article Influence: 9.9] [Reference Citation Analysis]
8 Zhang SP, Niu YN, Yuan N, Zhang AH, Chao D, Xu QP, Wang LJ, Zhang XG, Zhao WL, Zhao Y, Wang JR. Role of autophagy in acute myeloid leukemia therapy. Chin J Cancer 2013;32:130-5. [PMID: 22854065 DOI: 10.5732/cjc.012.10073] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
9 Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 2016;22:1067-75. [PMID: 26446942 DOI: 10.1158/1078-0432.CCR-15-1076] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
10 Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10-24. [PMID: 18843284 DOI: 10.1038/leu.2008.259] [Cited by in Crossref: 250] [Cited by in F6Publishing: 220] [Article Influence: 17.9] [Reference Citation Analysis]
11 Breitkreutz I, Podar K, Figueroa-vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Ann Hematol 2018;97:839-49. [DOI: 10.1007/s00277-018-3237-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
12 Chang-Yew Leow C, Gerondakis S, Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 2013;3:e105. [PMID: 23524590 DOI: 10.1038/bcj.2013.1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
13 Pennanen P, Kallionpää RA, Peltonen S, Nissinen L, Kähäri VM, Heervä E, Peltonen J. Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player. Mol Biol Rep 2021;48:1243-54. [PMID: 33486672 DOI: 10.1007/s11033-020-06128-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wang J, Lian H, Zhao Y, Kauss MA, Spindel S. Vitamin D3 induces autophagy of human myeloid leukemia cells. J Biol Chem. 2008;283:25596-25605. [PMID: 18628207 DOI: 10.1074/jbc.m801716200] [Cited by in Crossref: 88] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
15 Yamaguchi T, Kakefuda R, Tanimoto A, Watanabe Y, Tajima N. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide. Inflamm Res 2012;61:445-54. [PMID: 22245957 DOI: 10.1007/s00011-011-0431-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
16 Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011;117:2396-404. [PMID: 21163924 DOI: 10.1182/blood-2010-04-278788] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
17 Purushothaman A, Babitz SK, Sanderson RD. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem 2012;287:41288-96. [PMID: 23048032 DOI: 10.1074/jbc.M112.391417] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
18 Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Oncologist 2009;14:264-75. [PMID: 19286760 DOI: 10.1634/theoncologist.2008-0087] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
19 Okamoto K, Nakashima T, Shinohara M, Negishi-koga T, Komatsu N, Terashima A, Sawa S, Nitta T, Takayanagi H. Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. Physiological Reviews 2017;97:1295-349. [DOI: 10.1152/physrev.00036.2016] [Cited by in Crossref: 163] [Cited by in F6Publishing: 157] [Article Influence: 32.6] [Reference Citation Analysis]
20 Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol 2017;12:176-89. [PMID: 27654928 DOI: 10.2215/CJN.06100616] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
21 Malemud CJ. The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflamm. 2009;2009:698769. [PMID: 20339519 DOI: 10.1155/2009/698769] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
22 Matthes T, Mckee T, Dunand-sauthier I, Manfroi B, Park S, Passweg J, Huard B. Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow. Leukemia 2015;29:1901-8. [DOI: 10.1038/leu.2015.68] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
23 Mazière C, Louvet L, Gomila C, Kamel S, Massy Z, Mazière JC. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol 2009;221:572-8. [PMID: 19725047 DOI: 10.1002/jcp.21886] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
24 Okamoto K, Takayanagi H. Osteoimmunology. Cold Spring Harb Perspect Med 2019;9:a031245. [PMID: 29610150 DOI: 10.1101/cshperspect.a031245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
25 Ramakrishnan V, D'Souza A. Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep 2016;11:156-64. [PMID: 26922744 DOI: 10.1007/s11899-016-0315-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]